1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
IDL Diagnostics AB (publ)

IDL Diagnostics AB (publ)

IDLDX.ST
IDL Diagnostics AB (publ)SE flagStockholm Stock Exchange
0.49
SEK
+0.00
- -
111.96MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.02
0.02
0.01
- -
0.13
0.17
0.19
0.25
0.23
0.24
Basic EPS, GAAP
-0.19
-0.26
-0.25
-0.31
-0.58
-0.51
-0.57
-0.31
-0.53
-0.27
-0.26
-0.01
-0.05
-0.08
Free Cash Flow per Basic Share
- -
- -
-0.44
-0.57
-0.52
-0.4
-0.42
-0.25
-0.3
-0.08
-0.06
-0.01
-0.04
-0.03
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.1
-0.16
-1.01
-1.64
-2.19
-2.05
-2.85
-1.53
-1.73
-1.01
-1.2
-1.22
-1.27
-1.27
Tangible Book Value per Share
0.24
0.73
1.72
1.08
0.59
0.73
1.67
0.53
0.24
0.34
0.25
0.24
0.19
0.19
Basic Weighted Avg Shares
19
24
30
30
30
41
36
76
94
215
230
230
230
230
Sales/Revenue/Turnover
- -
- -
- -
- -
1
1
- -
- -
12
37
43
57
53
55
Operating Margin (%)
- -
- -
- -
-16,900.68
-3,439.34
-2,654.82
-4,680.59
-28,564.29
-423.61
-162.55
-139.4
-9.1
-20.19
-33.34
Depreciation Expense
- -
- -
- -
- -
3
4
5
5
25
47
46
6
4
- -
Net Income, GAAP
-4
-6
-7
-9
-17
-21
-21
-24
-50
-59
-59
-3
-12
-18
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-16,911.96
-3,440.2
-2,654.89
-4,680.81
-28,633.33
-417.01
-159.45
-137.78
-5.81
-22.88
-33.4
Working Capital
5
18
51
32
17
29
5
40
22
70
51
51
39
40
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15
13
11
10
Total Equity
16
36
73
63
47
55
80
56
217
223
164
160
148
149
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5.42
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
12
11
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
230
230
230
Market Capitalization
88
81
63

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
56
57
56
Cash, Cash Equivalents & STI
38
37
37
Accounts Receivable, Net
10
11
8
Inventories
6
7
8
Total Current Liabilities
15
18
16
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.79%
50.56%
-7.58%
Free Cash Flow
17.05%
25.41%
211.33%
Net Income, GAAP
44.27%
59.22%
264.02%
Sales/Revenue/Turnover
- -
2,886.31%
-7.54%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13
15
14
15
57
2025
15
10
11
16
53
2026
17
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.05
-0.06
- -
- -
-0.01
2025
-0.01
-0.06
-0.01
-0.01
-0.05
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Anders Hultman
Full Time Employees
20
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
KarlsbodavAegen 39 Stockholm Sweden 168 67
IPO Date
May 19, 2025
Website
idldiagnostics.com
Similar Companies
Stratec SE (0RAR.L)
Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
Monash IVF Group Limited (MVF.AX)
Izotropic Corporation (IZO.CN)
Quest Diagnostics Incorporated (DGX)
China Holdings, Inc. (CHHL)
Business
IDL Diagnostics AB (publ) (IDLDX.ST) develops, manufactures and markets in vitro diagnostic (IVD) tests focused on oncology and bacteriology for the detection and monitoring of diseases including bladder, prostate and other solid tumors as well as typhoid fever; its core products comprise UBC Rapid, a point-of-care urine test aiding in the diagnosis and monitoring of bladder cancer; TUBEX TF, a rapid diagnostic test for acute typhoid fever caused by Salmonella typhi; TK 210 ELISA (AroCell), a blood-based biomarker assay measuring thymidine kinase 1 for assessing therapy response and tumor cell proliferation in various cancers; and additional tumor markers such as TPS and cytokeratins licensed to strategic partners including Beckman Coulter for global distribution of ELISA-based assays. The company, founded in 2000 and headquartered in Bromma, Stockholm, Sweden, operates primarily in Europe and Asia through a network of international distributors and targets healthcare providers, clinical laboratories, contract research organizations and pharmaceutical companies in the life sciences tools and services sector. In May 2025, the company changed its name from AroCell AB (publ) to IDL Diagnostics AB (publ) to reflect its broadened product portfolio; recent developments include expanded sales of UBC tests with third-quarter 2025 volume up 52% year-over-year and year-to-date growth of 24%, deepened partnerships such as with Concile and Beckman Coulter, participation in the Sweden-Indonesia Sustainability Partnership (SISP) 2025 to strengthen presence in Indonesia, adoption of IFRS accounting standards for enhanced financial transparency starting in Q3 2025, and publication of a study demonstrating the combined use of serum TK1 and TPS blood tests to optimize treatment selection for advanced prostate cancer patients.